Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VcR-CVAD with Rituximab Maintenance for Untreated MCL
NCT00581776Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2005
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by University of Wisconsin–Madison. Started May 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00581776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581776.